Which knee treatment claims can you trust?

Does a worn X-ray mean you need surgery?

No, an X-ray is only part of that decision. Some knees look badly worn but still work well each day.

Your sleep, balance, walking, and daily tasks matter just as much. The X-ray can't decide when surgery belongs in your care.

Can PRP restore worn cartilage?

PRP means platelet-rich plasma: staff spin blood from your arm, collect platelets, and use the mix for a knee shot. The clinic gives that prepared mixture into the knee.

Cartilage forms the smooth cap over each bone end. PRP hasn't been shown to replace that worn cover, and careful studies don't all agree on soreness.

QC Kinetix offers visits to discuss PRP and the limits of the evidence. No clinic can promise how your knee will feel afterward.

How long can relief last?

Relief can last different lengths for different knees. A steroid shot uses cortisone medicine and may help for weeks.

Repeated steroid shots have been linked with more loss of the knee's smooth covering. They also didn't beat salt water for soreness when given often.

PRP relief isn't certain, so ask how long any benefit may last. Price and likely limits belong in the same talk.

Treat a fixed success rate or a promise lasting years with care. Your health and earlier care can change the likely answer.

What answer can you trust most?

No treatment makes a worn knee young again. The point is less soreness and more manageable daily movement.

If a promise sounds too neat, ask what the care involves. It also helps to ask what comes next after no relief.

Sources

1. FDA states verbatim: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production. There are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

2. The RESTORE trial randomized 288 adults aged 50+ with symptomatic mild-to-moderate medial knee OA to three weekly leukocyte-poor PRP injections or saline placebo. At 12 months, pain change was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and medial tibial cartilage volume change was -1.4% vs -1.2% (P=.81). 29 of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings 'do not support use of PRP for the management of knee OA.'

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. In a 2-year, double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, intra-articular triamcinolone 40 mg every 12 weeks caused significantly GREATER cartilage volume loss than saline (index-compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with NO significant difference in pain (-1.2 vs -1.9 on the WOMAC Likert pain subscale).

   McAlindon TE, LaValley MP, Harvey WF, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

4. A BMJ meta-analysis of 169 trials (21,163 participants) found viscosupplementation (hyaluronic acid injection) reduced knee OA pain by SMD -0.08 (95% CI -0.15 to -0.02) in the 24 large placebo-controlled trials — about 2.0 mm on a 100 mm scale, far below the prespecified 0.37 SMD minimal clinically important difference — and increased serious adverse events (RR 1.49, 95% CI 1.12 to 1.98). Trial sequential analysis showed conclusive evidence of clinical equivalence to placebo has existed since 2009.

   Pereira TV, Juni P, Saadat P, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

5. In January 2025 the FTC and the Georgia Attorney General obtained federal court orders permanently BANNING the co-founders of the Stem Cell Institute of America and related companies from marketing stem cell therapy, plus $5,155,146 in civil penalties and consumer refunds. The court found on summary judgment that the defendants published false and misleading advertisements about the efficacy and approval of stem cell injections for conditions including osteoarthritis; the affiliated clinic had charged up to $5,000 per injection, almost exclusively to elderly and disabled consumers.

   Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.

6. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee OA. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446), and centres claimed a mean clinical efficacy of 82% (SD 9.6%) — a figure with no support in the published evidence.

   Piuzzi NS, Ng M, Chughtai M, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. Journal of Knee Surgery, 2018. DOI: 10.1055/s-0037-1604443.

7. An analysis of internet-based marketing found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the United States — previously assumed to be a phenomenon of countries with lax medical regulation — and concluded regulators must better oversee this marketplace.

   Turner L, Knoepfler P. — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

8. An individual-participant-data meta-analysis of 621 placebo participants across 10 intra-articular injection trials found placebo response (>=20% pain reduction) was itself predictable: use of local anaesthetic and ultrasound guidance were associated with REDUCED odds of short-term placebo response, and longer trial duration with increased odds at midterm. Any single-arm 'our patients got better' claim about an injection is therefore uninterpretable.

   Zou K, et al. — Predictors of Placebo Response to Local (Intra-Articular) Therapy In Osteoarthritis: An Individual Participant Data Meta-Analysis.. Arthritis Care & Research, 2024. DOI: 10.1002/acr.25212.

9. In a placebo-surgery-controlled trial of 180 patients with knee OA, neither arthroscopic debridement nor arthroscopic lavage outperformed placebo surgery at ANY time point over 24 months on any of five self-reported pain/function scales or an objective walking and stair-climbing test.

   Moseley JB, O'Malley K, Petersen NJ, et al. — A controlled trial of arthroscopic surgery for osteoarthritis of the knee.. New England Journal of Medicine, 2002. DOI: 10.1056/NEJMoa013259.

10. In a double-blind, sham-controlled trial of 146 patients aged 35-65 with a degenerative medial meniscus tear and NO knee osteoarthritis, arthroscopic partial meniscectomy produced no significant benefit over sham surgery on any primary outcome at 12 months (Lysholm 21.7 vs 23.3 points; WOMET 24.6 vs 27.1; pain after exercise 3.1 vs 3.3).

    Sihvonen R, Paavola M, Malmivaara A, et al. — Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear.. New England Journal of Medicine, 2013. DOI: 10.1056/NEJMoa1305189.

11. A BMJ network meta-analysis of 10 large trials in 3,803 patients found glucosamine, chondroitin and their combination all failed to reach the prespecified minimal clinically important difference versus placebo for OA pain (glucosamine -0.4 cm, chondroitin -0.3 cm, combination -0.5 cm on a 10 cm VAS). Industry-independent trials showed SMALLER effects than commercially funded ones (P=0.02 for interaction).

    Wandel S, Juni P, Tendal B, et al. — Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis.. BMJ, 2010. DOI: 10.1136/bmj.c4675.

12. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-poor and leukocyte-rich PRP significantly improved 6-12 month WOMAC function versus placebo (MD -10.54 and -13.20 respectively) and both were superior to hyaluronic acid, with leukocyte-poor PRP ranked first (P-score 0.96) — a materially more favourable read of PRP than the RESTORE trial, which is why this corpus presents both.

    Journal of Orthopaedic Surgery and Research authors — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2026. DOI: 10.1186/s13018-026-06689-4.